COVID-19 pill rollout stymied by shortages as omicron rages

Craige Campbell, a website manager from Desert Hot Springs, California, began leaving messages with his doctor immediately after testing positive for COVID-19 and developing a 101-degree fever. Despite having no underlying health conditions, he was soon able to get a prescription.

The only pharmacy dispensing the drug was more than an hour’s drive away, so Campbell had a friend pick it up for him.

“I felt a bit privileged in a way,” he said. “The odds that it would land in my plate in the right amount of time were pretty extraordinary.”

At the same time, there is a shortage of antibody medications, the infused or injected drugs that can head off death and hospitalization. Only one of them, from GlaxoSmithKline, appears effective against omicron, and it, too, is being rationed.

Federal officials are limiting shipments of it to about 50,000 doses per week. This week, the government announced it is buying 600,000 more doses, on top of 400,000 purchased in November.

At the UPMC hospital system in Pennsylvania, the staff can treat fewer than 1,000 patients per week with antibodies, down from as many as 4,000 earlier in the pandemic.

Doctors and nurses around the U.S. have developed complex means of deciding who should get the scarce medications, based on patients’ symptoms, their underlying medical risks, where they live and whether they are healthy enough to travel for an infusion.

“What do we have on hand?” is the first question, said University of Maryland Medical Center’s Dr. Greg Schrank. “Among those therapies, what’s the most effective and how can we direct it to the people that we know are of greatest risk?”

The increasingly complicated treatment picture comes as exhausted, frustrated hospital workers try to manage rising admissions.

As of Sunday, nearly 128,000 Americans were in the hospital with COVID-19, surpassing the all-time high of around 125,000 last January. While fewer COVID-19 patients now require intensive care, the surge is pushing hospitals to the breaking point.

Considering that threat, Pfizer’s pill arrived just in time, Schrank said.

“It’s not going to turn the tide on the total number of cases, but it could really help dampen the impact on hospitals,” he said.



Source link

Leave a Reply

Blog article

What are CBG gummies good for?

Cannabigerol ( CBG ) gummies are a form of CBG available for consumption. They offer consumers CBG in an easy to use and edible format, for those who want the benefits CBG has without having to smoke it. Cannabigerol ( CBG ) Gummies as they’re known as, are a CBG product that is edible and […]

Read More
Blog article

Give Medicare direct contracting time to prove its value or expose its flaws

Healthcare experts have argued for years that we should move away from the dysfunctional, unsustainable fee-for-service Medicare reimbursement system and toward value-based models that incentivize better health outcomes such as reduced hospitalizations and post-acute care costs. Unfortunately, one of the federal Center for Medicare and Medicaid Innovation’s most promising value-based programs is facing a coordinated […]

Read More
Blog article

OSHA withdraws emergency enforcement of COVID vaccine mandate

The Occupational Safety and Health Administration is ceasing emergency enforcement of its COVID-19 mandate for large employers, but noted it’s not withdrawing it as a proposed rule. The withdrawal, which takes effect Jan. 26, follows the U.S. Supreme Court’s 6-3 decision on Jan. 13 to stop enforcement of the rule while appeals are pending at […]

Read More